MRNA241025P79000
- 18.65
- 0.000.00%
Moderna Newsroom
Earnings Preview: What to Expect From Moderna's Report
Why Moderna (MRNA) Dipped More Than Broader Market Today
Moderna Gets Sued by Northwestern University Over Patents Related to COVID Vaccines
Goldman's High Growth Investment Ratio Stocks: EA, AMZN, FANG, Etc
A Closer Look at Moderna's Options Market Dynamics
IDWeek 2024: Moderna's Norovirus Vaccine MRNA-1403 Shows Potential in Phase I/II Trial
TD Cowen Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60
Is Moderna Inc. (MRNA) the Best QQQ Stock to Buy According to Analysts?
Moderna, Inc. (MRNA): Worst Performing NASDAQ Stock in 2024
Options -- The Striking Price: Cut Your Tax Bill Using This Options Strategy -- Barron's
Cathie Wood's ARK Buys CRISPR, Intellia Stock, Sells Moderna
Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season
Trending Tickers: Netflix, Ferrari, American Express, Moderna and Boohoo
Moderna Options Spot-On: On October 17th, 122.91K Contracts Were Traded, With 554.07K Open Interest
On October 17th ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 122.91K options for the day, of which put options accounted for 82.14% of the total transactions,
Moderna plans to launch a combined vaccine for COVID-19 and influenza in Japan.
According to Kyodo News on October 17, Modena, a company from the USA, announced on October 17 that they are striving to launch a mixed vaccine for COVID-19 and seasonal influenza in Japan by 2027. CEO Stéphane Bancel mentioned that they are preparing the documents to be submitted to the Japanese Ministry of Health, Labor, and Welfare, hoping to apply within about half a year to a year. The company explained that if the vaccine they are developing can be put into practical use, one dose can provide two types of immunity, potentially reducing the burden on medical institutions and vaccine recipients.
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Helfie AI Appoints Healthcare Industry Leaders Antonin De Fougerolles and Cheryl Buxton to the Board of Directors
Express News | Moderna : Bernstein Initiates Coverage With Market-Perform Rating; Target Price $55
Northwestern University in the usa sues moderna (MRNA.US) for infringement of its LNP patent technology.
On Wednesday, Northwestern University in the USA filed a new patent lawsuit against moderna in the Federal Court of Delaware, accusing the company of abusing the school's innovative results to develop its flagship COVID-19 vaccine, Spikevax.
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock